![](https://investorshub.advfn.com/uicon/158678.png?cb=1661594561)
Sunday, November 02, 2014 7:43:35 AM
Help me understand the science at a level I can handle.
As I understand it there is a base known as a micelle or micelles to which a ligand or ligands must be added, in the same sense that one adds different flavors to water to make different versions of Koolaid....although I expect that the process of combining the materials is a touch more complicated. Do I have that correct?
I am also of the understanding that NNVC somehow generates the micelles themselves and the ligands are provided by an outside source. True?
In the above quote the co-founder, President and Chairman of NNVC indicates that the company is using scalable processes that, should the drug under development prove effective, quantities would be able to be manufactured rapidly enough to contain the current Ebola epidemic.
Please help me understand how he can be so confident in these purported scalable processes when it took what seemed like forever to muster the 200grams of Flucide to be provided for the tox test, a quantity that according to the company itself is less than a tenth of what is needed for a full test.
Does/did the company not have the micelles necessary "in stock" to get this done sooner?
Was the delay a function of the inability of the ligand supplier to provide the needed material on a timely basis?
Or did the "scalable process" used to combine the materials fail to perform as desired?
In the absence of clear answers to those questions I don't know how I can justify a belief in this:
“We are using scalable processes so that we can rapidly transfer synthesis to kg-scale production, which we believe will be sufficient to contain the spread of the current Ebola epidemic,”
It SOUNDS FANTASTIC, but the pace at which the Flucide tox samples were produced makes it hard for me to accept.
"I ated the purple berries"
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM